USA

Unum Therapeutics, a Cambridge, CA-based biotechnology company developing a universal, antibody-directed cellular immunotherapy, closed a $65m Series B financing. The round was led by new investor New Leaf Venture Partners, with participation from additional new investors Brace Pharma Capital, Cowen Private Investments, Jennison Associates (on behalf of certain clients), Novo A/S, Sabby Management LLC, Sectoral […]

USA

Regenxbio, a Rockville, Maryland-based gene therapy-focused biotech company, closed $70.5m in Series D funding. The round, which brought total funding to more than $110m, was led by Vivo Capital, Venrock and Brookside Capital with participation from a fund managed by Janus Capital Management, Jennison Associates, Perceptive Advisors, QVT Financial, Tourbillon Global Ventures, Sectoral Asset Management, […]

USA

Denali Therapeutics Inc., a San Francisco, CA-based biotechnology company that develops treatments for neurodegenerative diseases, launched with $217m in funding. The founding investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures, the Alaska Permanent Fund (represented by Crestline Investors), sovereign wealth funds, public mutual funds and private family offices. Led by Dr. Ryan Watts, Co-Founder, […]

USA

Precision BioSciences, a Research Triangle Park, N.C.-based genome editing company, closed a $25.6m Series A financing. The round was led by venBio with participation from Fidelity Biosciences, Amgen Ventures, Baxter Ventures, Osage University Partners, the Longevity Fund, and two public market investors. Robert Adelman of venBio and Ben Auspitz of Fidelity Biosciences will join Precision’s […]

USA

Symbiomix Therapeutics, a Newark, N.J.-based late-stage, privately held biopharmaceutical company, closed the third and final tranche of a $41m Series A financing. Investors included OrbiMed, Fidelity BioSciences, and HBM Partners, as well as financial services partner Square 1 Bank. The company intends to use the funds to advance SYM-1219 through Phase 3 and towards the […]

USA

Dimension Therapeutics, Inc., a Cambridge, MA-based rare disease company advancing novel, liver-directed treatments for diverse genetic disorders, completed a $65m Series B financing. The round was led by new investor New Leaf Venture Partners with participation from additional new investors Jennison Associates (on behalf of investors), Partner Fund Management, RA Capital Management, Rock Springs Capital, […]

USA

Quartet Health Inc., a New York-based behavioral health technology company, raised $7m in funding. The round was led by Annie Lamont at Oak HC/FT with participation from Shulman Ventures, Fidelity Biosciences, Polaris Partners and a number of CEOs who are serving as advisors to the company. In conjunction with the funding, Annie Lamont, Managing Partner […]

USA

Caribou Biosciences, a Berkeley, Calif.-based developer of technology-based solutions for cellular engineering and analysis, closed an $11m Series A financing round. Backers included Fidelity Biosciences, Novartis, Mission Bay Capital, 5 Prime Ventures, an undisclosed strategic partner, and Dr. Jennifer Doudna, Investigator, Howard Hughes Medical Institute, Professor, U.C. Berkeley and co-founder of Caribou. In conjunction with […]

USA

Semma Therapeutics, a Cambridge, MA-based developer of a cell therapy for Type 1 diabetes, closed a $44m Series A funding. The round was led by MPM Capital, with participation from Fidelity Biosciences, ARCH Venture Partners, and Medtronic participating. Alongside the equity financing, Semma entered into an undisclosed agreement with Novartis Pharmaceuticals. The company intends to […]

USA

Mersana Therapeutics, Inc., a Cambridgre, MA-based drug developer, raised $35m in Series B-1 financing. The round was led by existing investor New Enterprise Associates with participation from new investors Rock Springs Capital Management and Elliott Sigal, former head of R&D at Bristol-Myers Squibb (BMS), and current backers Pfizer Venture Investments and Fidelity Biosciences. The company […]

USA

TraceLink Inc., a Wakefield, MA-based provider of solutions for Life Sciences companies to protect patients From counterfeit drugs, raised $20m in venture funding. The round was led by Volition Capital, with participation from Fidelity Biosciences and existing investor FirstMark Capital. The company intends to use the funds to further invest in product development to support […]

USA

Iora Health, a Cambridge, Massachusetts-based healthcare company, raised $28m in Series C funding. Backers included Foundation Medical Partners, Rice Management Company, GE Ventures, Khosla Ventures, .406 Ventures, Fidelity Biosciences and Polaris Partners. The company intends to use the funds to expand operations aiming to double in size in 2015. Led by Rushika Fernandopulle, M.D., M.P.P., […]

China

Innovent Biologics, Inc., a Shangai, China-based biopharmaceutical company, raised $100m in Series C financing. The round was led by Legend Capital with participation from new investors Temasek and two additional backers, which joined Fidelity Biosciences, Fidelity Growth Partners Asia, Lilly Asia Ventures and Frontline Bioventures, who were original investors. The company intends to use the […]

USA

Regenxbio, a Washington, DC-based gene therapy biotech company, closed $30m in Series C funding. The round was led by Venrock and Brookside Capital with participation from Deerfield Management, FoxKiser and Fidelity BioSciences. In conjunction with the funding, Camille Samuels, a partner at Venrock and Michael Gelman joined Regenxbio’s board of directors. The company intends to […]

USA

Surface Oncology, a Cambridge, Mass.-based company developing cancer immunotherapies, closed a $35m Series A funding round. Backers included The Atlas Venture, which initially seeded the company in 2014, Fidelity Biosciences, Lilly Ventures, New Enterprise Associates (NEA), Amgen Ventures, Novartis Institute for Biomedical Research (NIBR), and Elliott Sigal, MD, former head of R&D at Bristol Myers […]

China

Adagene, a Suzhou Industrial Park, China-based biotech company, raised $8m in Series A funding. Backers included Fidelity Biosciences, Fidelity Asia Growth and WuXi Venture Fund. Led by Peter Luo, Ph.D., co-founder and CEO, Adagene is a developer of novel antibody therapeutics and since incorporating, in 2011, has created an expanding portfolio of libraries. A core […]

IrelandUSA

Novaerus, a Chicago, IL- and Dublin, Ireland-based company that applies plasma-based, airborne pathogen control technology to┬áimprove the business and quality of healthcare, completed a $10m funding round. Backers included Polaris Partners and Fidelity Biosciences. The company, which had previously received an investment from Oyster Capital Partners, intends to use the funds to continue to develop […]

USA

Blueprint Medicines, a Cambridge, MA-based developer of selective kinase inhibitors for genomically defined cancers, completed a $50m Series C financing. The round was led by Partner Fund Management with participation from new investors Wellington Management Company, RA Capital, Tavistock Life Sciences, Perceptive Advisors, Sabby Capital, Cowen Investments and Redmile Group and existing shareholders Biotechnology Value […]